Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study

[1]  M. Landray,et al.  Empagliflozin in Patients with Chronic Kidney Disease , 2022, The New England journal of medicine.

[2]  A. Morgan,et al.  The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus , 2022, Age and ageing.

[3]  J. McKenzie,et al.  Strengthening systematic reviews in public health: guidance in the Cochrane Handbook for Systematic Reviews of Interventions, 2nd edition , 2022, Journal of public health.

[4]  D. Giugliano,et al.  The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs , 2022, Cardiovascular Diabetology.

[5]  C. Hung,et al.  The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials , 2021, Diabetologia.

[6]  Deepak L. Bhatt,et al.  The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58 , 2021, Diabetes Care.

[7]  A. Sharif,et al.  Systematic Review of Cardiovascular Outcome Trials Using New Antidiabetic Agents in CKD Stratified by Estimated GFR , 2021, Kidney international reports.

[8]  J. Rosenstock,et al.  Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. , 2021, The New England journal of medicine.

[9]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[10]  Deepak L. Bhatt,et al.  Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. , 2020, The New England journal of medicine.

[11]  J. McMurray,et al.  Dapagliflozin in Patients with Chronic Kidney Disease. , 2020, The New England journal of medicine.

[12]  C. Cannon,et al.  Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. , 2020, The New England journal of medicine.

[13]  B. Zinman,et al.  Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial , 2020, Journal of the American Heart Association.

[14]  A. Kesselheim,et al.  Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis , 2020, Cardiovascular Diabetology.

[15]  R. Pratley,et al.  Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial , 2020, Diabetes, obesity & metabolism.

[16]  T. Vilsbøll,et al.  Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2019, The New England journal of medicine.

[17]  Deepak L. Bhatt,et al.  Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. , 2019, The lancet. Diabetes & endocrinology.

[18]  W. E. Sanabria,et al.  Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. , 2019, Lancet.

[19]  W. E. Sanabria,et al.  Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial , 2019, The Lancet.

[20]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[21]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.

[22]  Diane M. Miller,et al.  Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. , 2018, Lancet.

[23]  M. Nauck,et al.  Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns , 2018, Trends in Endocrinology & Metabolism.

[24]  R. Guthrie.  Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.

[25]  Neha J. Pagidipati,et al.  Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes , 2017, The New England journal of medicine.

[26]  M. Kahle,et al.  Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon‐like peptide‐1 receptor agonists: A systematic analysis of published clinical trials , 2017, Diabetes, obesity & metabolism.

[27]  Lawrence A Leiter,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.

[28]  S. Pocock,et al.  Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. , 2016, European heart journal. Cardiovascular pharmacotherapy.

[29]  John M Lachin,et al.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.

[30]  M. Fischereder,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.

[31]  P. Shekelle,et al.  Risk of bias: a simulation study of power to detect study-level moderator effects in meta-analysis , 2013, Systematic Reviews.

[32]  Suying Li,et al.  The synergistic relationship between estimated GFR and microalbuminuria in predicting long-term progression to ESRD or death in patients with diabetes: results from the Kidney Early Evaluation Program (KEEP). , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[33]  OUP accepted manuscript , 2022, Journal Of Public Health.

[34]  I. D. de Boer.  Liraglutide and Renal Outcomes in Type 2 Diabetes. , 2017, The New England journal of medicine.

[35]  F. Porzsolt,et al.  Using machine learning to predict laboratory test results , 2016, Annals of clinical biochemistry.

[36]  R. Mehrotra,et al.  Cardiovascular disease in chronic kidney disease , 2012 .

[37]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..